Free Trial

Perrigo (NYSE:PRGO) Cut to "Hold" at Wall Street Zen

Perrigo logo with Medical background

Key Points

  • Perrigo's stock rating has been downgraded from "buy" to "hold" by Wall Street Zen, signaling a shift in analysts' outlook on the company.
  • The company reported $0.60 earnings per share for the last quarter, exceeding estimates but with a 3.5% decline in year-over-year revenue.
  • Institutional investors control 95.91% of Perrigo's stock, indicating significant institutional confidence despite recent performance challenges.
  • Need better tools to track Perrigo? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Perrigo (NYSE:PRGO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Perrigo Price Performance

NYSE:PRGO traded down $0.06 during trading hours on Friday, reaching $28.08. 709,858 shares of the company's stock were exchanged, compared to its average volume of 849,362. The company has a market capitalization of $3.86 billion, a P/E ratio of -21.43 and a beta of 0.45. Perrigo has a 12 month low of $23.14 and a 12 month high of $30.93. The company has a quick ratio of 1.28, a current ratio of 2.36 and a debt-to-equity ratio of 0.82. The business's 50-day simple moving average is $26.98 and its two-hundred day simple moving average is $26.26.

Perrigo (NYSE:PRGO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The firm's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. Sell-side analysts expect that Perrigo will post 2.56 EPS for the current fiscal year.

Institutional Trading of Perrigo

A number of hedge funds have recently modified their holdings of PRGO. Price T Rowe Associates Inc. MD lifted its position in Perrigo by 41.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,073,026 shares of the company's stock worth $310,488,000 after buying an additional 3,227,487 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Perrigo by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 7,135,741 shares of the company's stock worth $200,085,000 after buying an additional 146,211 shares in the last quarter. Deprince Race & Zollo Inc. lifted its position in Perrigo by 1.1% in the 4th quarter. Deprince Race & Zollo Inc. now owns 4,557,844 shares of the company's stock worth $117,182,000 after buying an additional 50,728 shares in the last quarter. Sound Shore Management Inc. CT lifted its position in Perrigo by 23.1% in the 1st quarter. Sound Shore Management Inc. CT now owns 3,285,167 shares of the company's stock worth $92,116,000 after buying an additional 616,387 shares in the last quarter. Finally, Ion Asset Management Ltd. lifted its position in Perrigo by 0.5% in the 1st quarter. Ion Asset Management Ltd. now owns 2,833,894 shares of the company's stock worth $79,462,000 after buying an additional 13,894 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company's stock.

Perrigo Company Profile

(Get Free Report)

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.

Further Reading

Should You Invest $1,000 in Perrigo Right Now?

Before you consider Perrigo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.

While Perrigo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 High Short Interest Stocks to Buy Before November
HUGE Upside Ahead: The Fastest Growing ETFs in the Market
Next Tech Boom: AI Robots Are Coming Sooner Than You Think!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines